Why NewAmsterdam Pharma Company N.V.’s (NAMS) Stock Is Down 5.51%
As of Tuesday, July 28, NewAmsterdam Pharma Company N.V.’s NAMS share price has dipped by 5.51%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Stock Evaluator: NewAmsterdam Pharma Company N.V. (NAMS)
NewAmsterdam Pharma Company N.V. NAMS
$27.79
-0.67
-2.35%
July 31, 2026 4:00:00 PM
EST
Volume: 956,632
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Commentary & Analysis
Why NewAmsterdam Pharma Company N.V.’s (NAMS) Stock Is Up 5.69%
As of Wednesday, May 20, NewAmsterdam Pharma Company N.V.’s NAMS share price has surged by 5.69%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why NewAmsterdam Pharma Company N.V.’s (NAMS) Stock Is Up 7.28%
As of Monday, May 11, NewAmsterdam Pharma Company N.V.’s NAMS share price has surged by 7.28%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why NewAmsterdam Pharma Company N.V.’s (NAMS) Stock Is Up 11.74%
As of Friday, May 08, NewAmsterdam Pharma Company N.V.’s NAMS share price has surged by 11.74%, which has investors questioning if this is right time to sell.Omar Beirat
Why NewAmsterdam Pharma Company N.V.’s (NAMS) Stock Is Up 6.66%
As of Friday, May 08, NewAmsterdam Pharma Company N.V.’s NAMS share price has surged by 6.66%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | NAMS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,246.4 | $252.6 | 61% |
|
| Shares Out (Mil) | 121.7 | 52.3 | 67% |
|
| Institutional Ownership | 99.5% | 92.1% | 89% |
|
| Float (Mil) | 80.6 | 40.2 | 57% |
|
| Beta | 0.03 | 0.95 | 7% |
|
| Avg Daily Volume (000s) | 1,071 | 455 | 72% |
|
| Price Change (52-week) |
23.8% | 52.9% | 64% |
|
| Growth | NAMS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (96.3%) | (9.9%) | 2% |
|
| EPS (5yr) | (4.1%) | 16.0% | 26 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (33.3%) | (15.6%) | 16% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 12 | 13 | 12 | |
| Current EPS | ($0.488) | ($1.838) | ($1.296) | |
| Month Ago EPS | ($0.486) | ($1.827) | ($1.282) | |
| # Rev Up | 0 | 2 | 2 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.496) | ($1.940) | ($1.345) | |
| Year/Year Chg | 22.6% | 6.8% | (90.2%) | |
| Financials | NAMS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $23 | $38 | 14% |
|
| Net Income (TTM) (Mil) | ($213) | ($43) | 6% |
|
| EPS (TTM) | ($1.775) | ($1.600) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($142) | ($31) | 4% |
|
| Net Cash Flow (TTM) (Mil) | ($290) | $5 | 8% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 0% |
|
| Enterprise Value (Q1) (Mil) | $3,567 | $180 | 57% |
|
| Valuation | NAMS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.87 | 2.56 | 78% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | NAMS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 63.8% | 96% |
|
| Net Margin | (942.8%) | (67.3%) | 0% |
|
| ROA | (27.4%) | (49.8%) | 18% |
|
| ROE | (29.5%) | (55.5%) | 20% |
|
| Liabilities to Assets | 9.2% | 30.3% | 5% |
|
| F-Score | 3 | 3 | 19% |
|
NewAmsterdam Pharma Company N.V. did not pass any screens on 7/31/2026.
